Overview: Epstein-Barr NA-1 IgG (EBV NA-1 IgG) TestIntroduction: The Epstein-Barr NA-1 IgG Test detects IgG antibodies to Epstein-Barr virus nuclear antigen, indicating past infection causing fatigue or sore throat. Following 2023 IDSA guidelines, it uses an immunoassay for high sensitivity, aiding in infectious disease screening. This test is critical for guiding diagnosis, management, and improving outcomes in virology for patients with suspected EBV exposure.
Other Names: EBV Nuclear Antigen IgG Assay, EBV NA-1 Antibody Test.
FDA Status: Laboratory-developed test (LDT), meeting virology standards for diagnostic accuracy.
Historical Milestone: EBV antibody testing began in the 1960s with infectious mononucleosis research. NA-1 IgG assays emerged in the 1980s, and by the 2000s, high-sensitivity immunoassays improved accuracy.
Purpose: Diagnoses past EBV infection, guides management, and monitors antibody presence in patients with fatigue or sore throat history.
Test Parameters: 1. EBV Nuclear Antigen IgG
Pretest Condition: No fasting required. Collect serum or saliva at any time. Report symptoms like fatigue or sore throat, and list history of EBV-related conditions.
Specimen: 2-5 mL serum (SST) or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document fatigue, sore throat, or history of EBV-related conditions (e.g., mononucleosis). Include current medications or recent infections.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for supportive care.
Procedural Considerations: Uses an immunoassay to detect EBV NA-1 IgG antibodies. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Cross-reactivity with other viruses may cause false positives. Early infection may cause false negatives.
Clinical Significance: Positive IgG results indicate past EBV infection, guiding monitoring for complications. Negative results may require IgM or PCR testing.
Specialist Consultation: Consult an infectious disease specialist for result interpretation.
Additional Supporting Tests: EBV VCA IgG/IgM, EBV PCR, or lymphocyte count to confirm infection status.
Test Limitations: False positives may occur with related viruses. Results require clinical correlation.
References: IDSA EBV Guidelines, 2023; Clinical Infectious Diseases, Cohen JI, 2022.
